INHIBITION OF HIV-1 EXPRESSION BY DEFEROXAMINE, AN IRON CHELATING AGENT

甲磺酸去铁胺（去铁胺）用于治疗 检测肝细胞癌的抗HIV活性。 一些 肝细胞癌细胞系含有整合的HBV， 在其复制过程中出现了一个不寻常的逆转录步骤，这促使我们 测试DFX的抗逆转录病毒特性 H9细胞感染 HTLV-IIIB，并用不同浓度的药物治疗。 在第7天， 用PCR方法检测编码DNA样品中的HIV DNA。 DFX抑制了 p24抗原的表达和显著降低的 HIV DNA和抗原。 抑制作用呈剂量依赖性，30 μ M DFX 有效剂量为187 μ M AZT。 在第7天，存活率大于70%， 所有文化。 三个独立的实验进行了类似的结果 p24表达。 DFX体外抑制HIV-1的观察 提出了一种新的病毒抑制机制 进一步的研究正在 为解决这一问题并确定可能的协同作用而进行的 与目前正在临床试验中的其他药物一起使用。

Desferrioxamine mesylate (deferoxamine) used in the treatment of hepatocellular carcinoma was tested for anti-HIV activity. Some of the hepato cellular carcinoma cell lines contain integrated HBV which has an unusual reverse transcription step in its replication and this prompted us to test DFX for antiretroviral properties. H9 cells were infected with HTLV-IIIB and treated with varying concentrations of the drug. At day 7, coded samples of DNA were tested for HIV DNA by PCR. DFX inhibited the expression of p24 antigen and substantially reduced detectable levels of HIV DNA and antigen. The inhibition was dose dependant, with 30 uM DFX being effective as 187 uM AZT. Viability was greater than 70% at day 7 in all cultures. Three independent experiments were done with similar results for p24 expression. The observation of in vitro inhibition of HIV-1 by DFX suggests a new mechanism of viral inhibition. Further studies are being conducted to address this question as well as to ascertain possible synergy with other agents currently in clinical trials.